Fmr LLC Has $948,000 Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Fmr LLC increased its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 33.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 49,248 shares of the company’s stock after purchasing an additional 12,377 shares during the period. Fmr LLC owned about 0.06% of Syndax Pharmaceuticals worth $948,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of SNDX. Mirae Asset Global Investments Co. Ltd. increased its holdings in Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after buying an additional 541 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in Syndax Pharmaceuticals in the second quarter valued at about $27,000. Values First Advisors Inc. bought a new stake in Syndax Pharmaceuticals in the third quarter valued at about $30,000. nVerses Capital LLC acquired a new position in Syndax Pharmaceuticals in the second quarter worth about $33,000. Finally, Inspire Investing LLC lifted its stake in Syndax Pharmaceuticals by 15.0% during the second quarter. Inspire Investing LLC now owns 17,290 shares of the company’s stock worth $355,000 after purchasing an additional 2,258 shares during the period.

Syndax Pharmaceuticals Price Performance

Shares of Syndax Pharmaceuticals stock opened at $13.79 on Tuesday. The firm has a 50 day simple moving average of $17.81 and a 200 day simple moving average of $19.45. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $13.26 and a fifty-two week high of $25.34. The firm has a market cap of $1.18 billion, a P/E ratio of -3.80 and a beta of 0.86.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same period last year, the business posted ($0.73) earnings per share. On average, sell-side analysts expect that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current year.

Analyst Upgrades and Downgrades

SNDX has been the subject of a number of recent research reports. The Goldman Sachs Group increased their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 10th. UBS Group began coverage on shares of Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a “buy” rating and a $37.00 target price on the stock. StockNews.com cut shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 23rd. Finally, Stifel Nicolaus boosted their price target on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, October 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.64.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).